Genmab A/S
GMAB- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001434265
No open-market purchases or sales by Genmab A/S insiders were filed in the last 90 days; 291 institutions reported holding it in 13F filings for Q2 2026, worth $2.81B in total; no superinvestor holds it.
Other share classesGNMSF
Q2 2022 vs. Q1 2022
How the institutions holding Genmab A/S changed between Q1 2022 and Q2 2022.
All holders in Q2 2022All holders in Q1 2022
| Measure | Q1 2022 | Of which not filed for Q2 2022 | Q2 2022 | Change |
|---|---|---|---|---|
| Holders | 204 | 4 | 181 | −19 |
| Shares | 39.0M | 824.6K | 35.6M | −2.64M (−6.9%) |
| Value | $1.41B | $29.8M | $1.15B | −$231.7M (−16.8%) |
4 institutions that held it in Q1 2022 haven't filed for Q2 2022 yet. Not filing isn't selling, so the changes leave them out.
New holders (18)
Institutions that held Genmab A/S at the end of Q2 2022 but not at the end of Q1 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Capricorn Fund Managers Ltd | 148,411 | $4.82M | 0.88% |
| Advisors Asset Management, Inc. | 53,021 | $1.72M | 0.03% |
| Capital Group Private Client Services, Inc. | 36,221 | $1.18M | 0.02% |
| Connective Portfolio Management, LLC | 18,000 | $585.0K | 1.00% |
| Eagle Asset Management Inc | 13,260 | $430.0K | 0.00% |
| Capital Fund Management S.A. | 12,720 | $413.3K | 0.01% |
| Susquehanna International Group Ltd. | 10,300 | $335.0K | 0.08% |
| Gyon Technologies Capital Management, LP | 6,841 | $222.0K | 0.06% |
| International Biotechnology Trust PLC | 1,857 | $57.2K | 1.13% |
| Venture Visionary Partners LLC | 949 | $30.8K | 0.00% |
| Private Trust Co NA | 649 | $21.0K | 0.00% |
| Allworth Financial LP | 290 | $9.00K | 0.00% |
| Plante Moran Financial Advisors, LLC | 151 | $5.00K | 0.00% |
| Ronald Blue Trust, Inc. | 118 | $4.00K | 0.00% |
| Schubert & Co | 81 | $3.00K | 0.00% |
| Harbour Investments, Inc. | 24 | $1.00K | 0.00% |
| Sargent Bickham Lagudis LLC | 46 | $1.00K | 0.00% |
| Steward Financial Group LLC | 9 | $0 | 0.00% |
Sold out (37)
Institutions that held Genmab A/S at the end of Q1 2022 and filed for Q2 2022 without it.
Not filed for Q2 2022 yet (4)
Institutions that held Genmab A/S at the end of Q1 2022 and haven't filed a 13F for Q2 2022. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q1 2022 | Value, Q1 2022 |
|---|---|---|
| Parametric Portfolio Associates LLC | 823,618 | $29.8M |
| Kings Point Capital Management | 625 | $23.0K |
| SJS Investment Consulting Inc. | 342 | $12.0K |
| Dixon Hughes Goodman Wealth Advisors LLC | 39 | $1.00K |